A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects with Schizophrenia, Followed by a 40-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
OLANZAPINERISPERIDONEPlacebo for over-encapsulated comparatorsARIPIPRAZOLERoluperidonePlacebo for Roluperidone
Eligibility
Age group
18-64 years
Sex
Female, Male
Primary endpoint
Change from Baseline in NSFS
Endpoint detail
Change from Baseline in the PSP Total score, Change from Baseline in the CGI-S score
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.